Ranbaxy: Court Recognizes Fraud-On-The-FDA Antitrust Claim
The pharmaceutical sector is no stranger to major antitrust actions. Numerous cases focus on drug companies' efforts to preserve exclusivity periods — time periods when the patent laws or drug regulations...To view the full article, register now.
Already a subscriber? Click here to view full article